Abstract Background: Coronavirus disease 2019 (COVID-19) is a potentially fatal disease. clinical practice shows that Chinese Patent Medicine (CPM) has played an important role in the outbreak, Among them, Jinhua Qinggan granules, Lianhua Qingwen capsule, and Xuebiqing injection have an effect in treating COVID-19 patients, but it has not been systematically evaluated for efficacy and safety. We provide a protocol for systematic review and meta-analysis. Materials and methods: Retrieved the database, including the China National Knowledge Infrastructure, Chinese Biomedical Database, Wan Fang database, and PubMed. The quality of each study is assessed according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. Using Manager 5.3 software and STATA 16.0 software were used to perform the meta-analysis. Results: The systematic review and meta-analysis aims to review and pool current clinical outcomes of CPM combined with routine western medicine (RWM) for the treatment of COVID-19. Conclusion: This study will provide evidence of CPM (including Jinhua Qinggan granule, Lianhua Qingwen capsule, and Xuebiqing injection) for the treatment on COVID-19 patients. INPLASY Registration number: INPLASY202050050.
【저자키워드】 Meta-analysis, protocol, systematic review, corona virus disease 2019, Chinese patent medicine, routine western medicine, 【초록키워드】 COVID-19, Treatment, review, Coronavirus disease 2019, database, Clinical outcome, CPM, Medicine, China, Registration, outbreak, Efficacy and safety, COVID-19 patients, Clinical practice, Evidence, Patent, criteria, Infrastructure, Chinese, injection, material, Stata, fatal disease, treating COVID-19 patients, evaluated, were used, Fang, granules, Handbook, 【제목키워드】 COVID-19, Treatment, coronavirus disease, therapeutic efficacy, Chinese,